Primarily utilized to monitor ovarian cancer treatment efficacy, elevated CA-125 levels may manifest in uterine, cervical, pancreatic, hepatic, colonic, mammary, pulmonary, and gastrointestinal cancers and specific noncancerous conditions [22,23]. This evidence concerns the gene MUC16 and ovarian cancer.